The effect and therapeutic compliance of adjuvant therapy in patients with cholangiocarcinoma after R0 resection: a retrospective study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: This study aimed to compare clinical outcomes between surveillance and adjuvant therapy (AT) groups after R0 resection for cholangiocarcinoma (CCA). Methods: A total of 154 patients who underwent R0 resection for CCA at the Daegu Catholic University Medical Center between January 2010 and December 2019 were included. Overall survival (OS) and progression-free survival (PFS) were analyzed. Results: The median follow-up duration was 899 days. There were 109 patients in the AT group and 45 patients in the surveillance group. The patients in the AT group were younger (67 years vs. 74 years, p<0.001) and included more males (64.2% vs. 46.7%, p=0.044). The proportion of patients with stage III CCA was larger in the AT group than in the surveillance group (13.8% vs. 2.2%, p=0.005). In addition, AT did not improve OS (5-year OS rate, 69.3% in the AT group vs. 64.2% in the surveillance group, p=0.806) or PFS (5-year PFS rate, 42.6% in the AT group vs. 48.9% in the surveillance group, p=0.113). In multivariate analysis using the Cox proportional hazards model, stage III CCA (hazard ratio [HR], 10.81; 95% confidence interval [CI], 2.92–40.00; p<0.001) was a significant predictor of OS. American Society of Anesthesiologists classification II (HR, 0.50; 95% CI, 0.31–0.81; p=0.005), and American Joint Committee on Cancer stages II (HR, 3.14; 95% CI, 1.25–7.89; p=0.015) and III (HR, 8.08; 95% CI, 2.80–23.32; p<0.001) were independent predictors of PFS. Conclusion: AT after R0 resection for CCA did not improve OS or PFS.
Abstract
Background: This study aimed to compare clinical outcomes between surveillance and adjuvant therapy (AT) groups after R0 resection for cholangiocarcinoma (CCA). Methods: A total of 154 patients who underwent R0 resection for CCA at the Daegu Catholic University Medical Center between January 2010 and December 2019 were included. Overall survival (OS) and progression-free survival (PFS) were analyzed. Results: The median follow-up duration was 899 days. There were 109 patients in the AT group and 45 patients in the surveillance group. The patients in the AT group were younger (67 years vs. 74 years, p<0.001) and included more males (64.2% vs. 46.7%, p=0.044). The proportion of patients with stage III CCA was larger in the AT group than in the surveillance group (13.8% vs. 2.2%, p=0.005). In addition, AT did not improve OS (5-year OS rate, 69.3% in the AT group vs. 64.2% in the surveillance group, p=0.806) or PFS (5-year PFS rate, 42.6% in the AT group vs. 48.9% in the surveillance group, p=0.113). In multivariate analysis using the Cox proportional hazards model, stage III CCA (hazard ratio [HR], 10.81; 95% confidence interval [CI], 2.92–40.00; p<0.001) was a significant predictor of OS. American Society of Anesthesiologists classification II (HR, 0.50; 95% CI, 0.31–0.81; p=0.005), and American Joint Committee on Cancer stages II (HR, 3.14; 95% CI, 1.25–7.89; p=0.015) and III (HR, 8.08; 95% CI, 2.80–23.32; p<0.001) were independent predictors of PFS. Conclusion: AT after R0 resection for CCA did not improve OS or PFS.
참고문헌 (27)
- Brindley PJ, "Cholangiocarcinoma", Nat Rev Dis Primers, 7, pp.65~ (2021)
- Khan SA, "Cholangiocarcinoma : epidemiology and risk factors", Liver Int, 39(Suppl 1), pp.19~31 (2019)
- Belkouz A, "Advances in adjuvant therapy of biliary tract cancer : an overview of current clinical evidence based on phase II and III trials", Crit Rev Oncol Hematol, 151, pp.102975~ (2020)
- Allen MJ, "A review of current adjuvant and neoadjuvant systemic treatments for cholangiocarcinoma and gallbladder carcinoma", Hepatoma Res, 7, pp.73~ (2021)
- Byung-Woo Kim, "Incidence and Overall Survival of Biliary Tract Cancers in South Korea from 2006 to 2015: Using the National Health Information Database", Gut and Liver, 13(1), pp.104~113 (2019), 거트앤리버 소화기연관학회협의회[DOI]
- Takada T, "Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? : a phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma", Cancer, 95, pp.1685~1695 (2002)
- Neoptolemos JP, "Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma : the ESPAC-3 periampullary cancer randomized trial", JAMA, 308, pp.147~156 (2012)
- Primrose JN, "Capecitabine compared with observation in resected biliary tract cancer(BILCAP) : a randomised, controlled, multicentre, phase 3 study", Lancet Oncol, 20, pp.663~673 (2019)
- Ebata T, "Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer", Br J Surg, 105, pp.192~202 (2018)
- Edeline J, "Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer(PRODIGE 12-ACCORD 18-UNICANCER GI) : a randomized phase III study", J Clin Oncol, 37, pp.658~667 (2019)
- Kim YS, "The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection", Chin J Cancer, 36, pp.9~ (2017)
- McNamara MG, "Outcome of adjuvant therapy in biliary tract cancers", Am J Clin Oncol, 38, pp.382~387 (2015)
- Miyata Y, "The efficacy of S-1 as adjuvant chemotherapy for resected biliary tract carcinoma : a propensity score-matching analysis", J Clin Med, 10, pp.925~ (2021)
- Wang L, "Postoperative adjuvant therapy following radical resection for intrahepatic cholangiocarcinoma : a multicenter retrospective study", Cancer Med, 9, pp.2674~2685 (2020)
- Murakami Y, "Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma", Ann Surg, 250, pp.950~956 (2009)
- Yamanaka K, "A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer", Int J Clin Oncol, 19, pp.485~489 (2014)
- Kim YS, "Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma", Cancer Chemother Pharmacol, 77, pp.979~985 (2016)
- Kim YS, "The role of adjuvant therapy after R0 resection for patients with intrahepatic and perihilar cholangiocarcinomas", Cancer Chemother Pharmacol, 79, pp.99~106 (2017)
- Bergeat D, "Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma : a propensity score analysis from a French multicentric cohort", Langenbecks Arch Surg, 403, pp.701~709 (2018)
- Yin L, "The efficiency and regimen choice of adjuvant chemotherapy in biliary tract cancer : a STROBE-compliant retrospective cohort study", Medicine(Baltimore), 97, pp.e13570~ (2018)
- "NCCN Practice Guidelines in Oncology. Hepatobiliary cancers, version 5" (2021)[URL]
- Ringborg U, "Adjuvant chemotherapy : a discussion of some basic principles", Acta Oncol, 30, pp.251~253 (1991)
- Mosteller RD, "Simplified calculation of body-surface area", N Engl J Med, 317, pp.1098~ (1987)
- Saam J, "Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens", Clin Colorectal Cancer, 10, pp.203~206 (2011)
- Capitain O, "Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing : a phase II, proof-of-concept study", Clin Colorectal Cancer, 11, pp.263~267 (2012)
- Chauhan A, "Post-operative morbidity results in decreased long-term survival after resection for hilar cholangiocarcinoma", HPB(Oxford), 13, pp.139~147 (2011)
- Hurwitz EE, "Adding examples to the ASA-Physical Status Classification improves correct assignment to patients", Anesthesiology, 126, pp.614~622 (2017)